Clinical trial

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

NCT05378204

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-06-23

PhaseNA

Study timeline

Study start (actual)2022-06-23Date precision: day

Registry last updated2026-02-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

Main study:OTHER

Sub-study:OTHER

Sponsors & collaborators

Institut Claudius Regaudlead sponsor

Mapped research locations

ParisFrance4 MontpellierFrance2 ToulouseFrance1 MarseilleFrance1 LyonFrance1 LilleFrance1 BordeauxFrance1 RennesFrance1 DijonFrance1 Clermont-FerrandFrance1 CaenFrance1 VillejuifFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05378204 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.